Shears S B, Storey D J, Morris A J, Cubitt A B, Parry J B, Michell R H, Kirk C J
Biochem J. 1987 Mar 1;242(2):393-402. doi: 10.1042/bj2420393.
We have augmented our previous studies [Storey, Shears, Kirk & Michell (1984) Nature (London) 312, 374-376] on the subcellular location and properties of Ins(1,4,5)P3 (inositol 1,4,5-trisphosphate) phosphatases in rat liver and human erythrocytes. We also investigate Ins(1,3,4)P3 (inositol 1,3,4-trisphosphate) metabolism by rat liver. Membrane-bound and cytosolic Ins(1,4,5)P3 phosphatases both attack the 5-phosphate. The membrane-bound enzyme is located on the inner face of the plasma membrane, and there is little or no activity associated with Golgi apparatus. Cytosolic Ins(1,4,5)P3 5-phosphatase (Mr 77,000) was separated by gel filtration from Ins(1,4)P2 (inositol 1,4-bisphosphate) and inositol 1-phosphate phosphatases (Mr 54,000). Ins(1,4,5)P3 5-phosphatase activity in hepatocytes was unaffected by treatment of the cells with insulin, vasopressin, glucagon or dibutyryl cyclic AMP. Ins(1,4,5)P3 5-phosphatase activity in cell homogenates was unaffected by changes in [Ca2+] from 0.1 to 2 microM. After centrifugation of a liver homogenate at 100,000 g, Ins(1,3,4)P3 phosphatase activity was largely confined to the supernatant. The sum of the activities in the supernatant and the pellet exceeded that in the original homogenate. When these fractions were recombined, Ins(1,3,4)P3 phosphatase activity was restored to that observed in unfractionated homogenate. Ins(1,3,4)P3 was produced from Ins(1,3,4,5)P4 (inositol 1,3,4,5-tetrakisphosphate) and was metabolized to a novel InsP2 that was the 3,4-isomer. Ins(1,3,4)P3 phosphatase activity was not changed by 50 mM-Li+ or 0.07 mM-Ins(1,4)P2 alone, but when added together these agents inhibited Ins(1,3,4)P3 metabolism. In Li+-treated and vasopressin-stimulated hepatocytes, Ins(1,4)P2 may reach concentrations sufficient to inhibit Ins(1,3,4)P3 metabolism, with little effect on Ins(1,4,5)P3 hydrolysis.
我们扩展了之前关于大鼠肝脏和人类红细胞中肌醇-1,4,5-三磷酸(Ins(1,4,5)P3)磷酸酶的亚细胞定位及特性的研究[斯托里、希尔斯、柯克和米切尔(1984年),《自然》(伦敦)312, 374 - 376]。我们还研究了大鼠肝脏中肌醇-1,3,4-三磷酸(Ins(1,3,4)P3)的代谢。膜结合型和胞质型Ins(1,4,5)P3磷酸酶均作用于5-磷酸基团。膜结合型酶位于质膜内表面,与高尔基体相关的活性很少或没有。通过凝胶过滤将胞质型Ins(1,4,5)P3 5-磷酸酶(分子量77,000)与肌醇-1,4-二磷酸(Ins(1,4)P2)和肌醇-1-磷酸磷酸酶(分子量54,000)分离。用胰岛素、血管加压素、胰高血糖素或二丁酰环磷酸腺苷处理肝细胞后,肝细胞中Ins(1,4,5)P3 5-磷酸酶活性不受影响。细胞匀浆中Ins(1,4,5)P3 5-磷酸酶活性在[Ca2+]从0.1微摩尔/升至(2)微摩尔/升变化时不受影响。肝脏匀浆在(100,000)克离心后,Ins(1,3,4)P3磷酸酶活性主要存在于上清液中。上清液和沉淀中的活性总和超过了原始匀浆中的活性。当将这些组分重新混合时,Ins(1,3,4)P3磷酸酶活性恢复到未分级匀浆中观察到的水平。Ins(1,3,4)P3由肌醇-1,3,4,5-四磷酸(Ins(1,3,4,5)P4)产生,并代谢为一种新的肌醇二磷酸,即3,4-异构体。单独的(50)毫摩尔/升锂离子或(0.07)毫摩尔/升Ins(1,4)P2不会改变Ins(1,3,4)P3磷酸酶活性,但当两者一起添加时,这些试剂会抑制Ins(1,3,4)P3代谢。在锂离子处理和血管加压素刺激的肝细胞中,Ins(1,4)P2可能达到足以抑制Ins(1,3,4)P3代谢的浓度,而对Ins(1,4,5)P3水解影响很小。